FASN, fatty acid synthase, 2194

N. diseases: 245; N. variants: 6
Source: ALL
Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs2228305
rs2228305
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0028754
Disease:
Obesity
0.030 GeneticVariation BEFREE Val1483Ile in FASN gene is linked to central obesity and insulin sensitivity in adult white men. 19300427 2009
dbSNP: rs2228305
rs2228305
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0028754
Disease:
Obesity
0.030 GeneticVariation BEFREE In conclusion, our findings suggest a sex-specific protective effect of the Val1483Ile polymorphism in FAS for obesity in Caucasian boys. 16788566 2007
dbSNP: rs2228305
rs2228305
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0028754
Disease:
Obesity
0.030 GeneticVariation BEFREE Our findings indicate that the Val1483Ile substitution in FAS is protective against obesity in Pima Indians, an effect possibly explained by the role of this gene in the regulation of substrate oxidation. 15220220 2004
dbSNP: rs200842352
rs200842352
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0020676
Disease:
Hypothyroidism
0.010 GeneticVariation BEFREE Genotyping results revealed that two mutations, c.G7192T (p.A2398S) in the FASN gene and c.C1883G (p.T628R) in the APOBR gene, were fully co‑segregated with established hypothyroidism phenotypes in the family. 30272292 2018
dbSNP: rs4246444
rs4246444
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0684249
Disease:
Carcinoma of lung
0.010 GeneticVariation BEFREE SNP rs4246444 had a significant association with lung cancer recurrence under additive model (hazard ratio [HR], 0.82; 95% confidence interval [95%CI], 0.67-1.00; p=0.05). 25227797 2014
dbSNP: rs4246444
rs4246444
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C1306460
Disease:
Primary malignant neoplasm of lung
0.010 GeneticVariation BEFREE SNP rs4246444 had a significant association with lung cancer recurrence under additive model (hazard ratio [HR], 0.82; 95% confidence interval [95%CI], 0.67-1.00; p=0.05). 25227797 2014
dbSNP: rs4246444
rs4246444
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0242379
Disease:
Malignant neoplasm of lung
0.010 GeneticVariation BEFREE SNP rs4246444 had a significant association with lung cancer recurrence under additive model (hazard ratio [HR], 0.82; 95% confidence interval [95%CI], 0.67-1.00; p=0.05). 25227797 2014
dbSNP: rs2228305
rs2228305
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0038443
Disease:
Stress, Psychological
0.010 GeneticVariation BEFREE The Val1483Ile polymorphism in the FASN was associated with depressive symptoms under the influence of psychological stress. 21641044 2011
dbSNP: rs2228305
rs2228305
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0086132
Disease:
Depressive Symptoms
0.010 GeneticVariation BEFREE The Val1483Ile polymorphism in the FASN was associated with depressive symptoms under the influence of psychological stress. 21641044 2011
dbSNP: rs17848939
rs17848939
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0028754
Disease:
Obesity
0.010 GeneticVariation BEFREE Several polymorphisms in the FASN (rs62078748, rs2229422, rs2229425, and rs17848939) were nominally associated with obesity in case-control studies including 446 obese subjects (BMI >or=30 kg/m(2)) and 389 lean controls (BMI <or=25 kg/m(2)) (adjusted P < 0.05). 19876008 2010
dbSNP: rs2229422
rs2229422
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0011860
Disease:
Diabetes Mellitus, Non-Insulin-Dependent
0.010 GeneticVariation BEFREE The strongest significant effect was found for rs2229422 (P = 1.3 x 10(-5) adjusted for age, sex, type 2 diabetes status), which was supported by associations with BMI, waist-to-hip ratio (WHR), fasting plasma insulin and glucose infusion rate (adjusted P < 0.05). 19876008 2010
dbSNP: rs2229425
rs2229425
Entrez Id: 2194
Gene Symbol: FASN
FASN
CUI: C0028754
Disease:
Obesity
0.010 GeneticVariation BEFREE Several polymorphisms in the FASN (rs62078748, rs2229422, rs2229425, and rs17848939) were nominally associated with obesity in case-control studies including 446 obese subjects (BMI >or=30 kg/m(2)) and 389 lean controls (BMI <or=25 kg/m(2)) (adjusted P < 0.05). 19876008 2010